Literature DB >> 7183189

The drug abuse screening test.

H A Skinner.   

Abstract

The Drug Abuse Screening Test (DAST) was designed to provide a brief instrument for clinical screening and treatment evaluation research. The 28 self-report items tap various consequences that are combined in a total DAST score to yield a quantitative index of problems related to drug misuse. Measurement properties of the DAST were evaluated using a clinical sample of 256 drug/alcohol abuse clients. The internal consistency reliability estimate was substantial at .92, and a factor analysis of item intercorrelations suggested an unidimensional scale. With respect to response style biases, the DAST was only moderately correlated with social desirability and denial. Concurrent validity was examined by correlating the DAST with background variables, frequency of drug use during the past 12 months, and indices of psychopathology. Although these findings support the usefulness of the DAST for quantifying the extent of drug involvement within a help-seeking population, further validation work is needed in other populations and settings.

Entities:  

Mesh:

Year:  1982        PMID: 7183189     DOI: 10.1016/0306-4603(82)90005-3

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   3.913


  733 in total

Review 1.  The evaluation of parental fitness in termination of parental rights cases: a functional-contextual perspective.

Authors:  S T Azar; A F Lauretti; B V Loding
Journal:  Clin Child Fam Psychol Rev       Date:  1998-06

Review 2.  Referral and screening for substance abuse treatment in jails.

Authors:  R H Peters
Journal:  J Ment Health Adm       Date:  1992

3.  Early Initiation of Substance Use as an Indicator of Problematic Substance Use Among Young Men Who Have Sex with Men (YMSM).

Authors:  Aleksandar Kecojevic; Corey H Basch; Stephen E Lankenau
Journal:  Subst Use Misuse       Date:  2017-08-04       Impact factor: 2.164

4.  In vivo evidence for greater amphetamine-induced dopamine release in pathological gambling: a positron emission tomography study with [(11)C]-(+)-PHNO.

Authors:  I Boileau; D Payer; B Chugani; D S S Lobo; S Houle; A A Wilson; J Warsh; S J Kish; M Zack
Journal:  Mol Psychiatry       Date:  2013-12-10       Impact factor: 15.992

5.  GRM8 genotype is associated with externalizing disorders and greater inter-trial variability in brain activation during a response inhibition task.

Authors:  Lance O Bauer; Jonathan M Covault
Journal:  Clin Neurophysiol       Date:  2020-04-02       Impact factor: 3.708

6.  How patients understand the term "nonmedical use" of prescription drugs: insights from cognitive interviews.

Authors:  Jennifer McNeely; Perry N Halkitis; Ariana Horton; Rubina Khan; Marc N Gourevitch
Journal:  Subst Abus       Date:  2014       Impact factor: 3.716

7.  Affect and craving: positive and negative affect are differentially associated with approach and avoidance inclinations.

Authors:  Robert C Schlauch; Daniel Gwynn-Shapiro; Paul R Stasiewicz; Danielle S Molnar; Alan R Lang
Journal:  Addict Behav       Date:  2012-12-08       Impact factor: 3.913

8.  Alterations in the neural circuitry for emotion and attention associated with posttraumatic stress symptomatology.

Authors:  Jasmeet Pannu Hayes; Kevin S Labar; Christopher M Petty; Gregory McCarthy; Rajendra A Morey
Journal:  Psychiatry Res       Date:  2009-02-23       Impact factor: 3.222

9.  Impact of intimate partner violence on clinic attendance, viral suppression and CD4 cell count of women living with HIV in an urban clinic setting.

Authors:  Jocelyn C Anderson; Jacquelyn C Campbell; Nancy E Glass; Michele R Decker; Nancy Perrin; Jason Farley
Journal:  AIDS Care       Date:  2018-04

10.  Demographic and socioenvironmental predictors of premorbid marijuana use among patients with first-episode psychosis.

Authors:  Luca Pauselli; Michael L Birnbaum; Beatriz Paulina Vázquez Jaime; Enrico Paolini; Mary E Kelley; Beth Broussard; Michael T Compton
Journal:  Schizophr Res       Date:  2018-02-04       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.